15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Arcutis Biotherapeutics Inc, 6 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $29.00 to $40.00, so the covering firms are broadly aligned. The average target of $35.57 sits 49% above the current $23.83. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees revenue growth near 32% this year and 30% next, consensus EPS building from about $0.23 next quarter toward $1.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy686%
Hold114%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Arcutis Biotherapeutics Inc.
As of Sep, 6 of 7 firms rate ARQT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ARQT EPS & revenue forecast
EPS · NEXT QUARTER
$0.23
Range $0.03 – $0.39 · 6 analysts · +76% YoY
Next period, 6 analysts expect Arcutis Biotherapeutics Inc to earn $0.23 a share (range $0.03 – $0.39), versus $0.13 a year earlier. Full-year consensus is $0.41, growing to $1.30 the year after.
REVENUE · NEXT QUARTER
$160.1M
Range $153.6M – $167.4M · 6 analysts · +30% YoY
Revenue is expected to reach $160.1M (range $153.6M – $167.4M), +30.0% year-over-year. Full-year consensus is $536.9M, rising to $685.5M next year.
Top analysts covering Arcutis Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARQT.
#1
Serge Belanger
Needham · Rank #105
Buy
$40.00+67.9% to target
Overall win rate
48%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #248
Buy
$34.00+42.7% to target
Overall win rate
35%
+ Follow
#3
Seamus Fernandez
Guggenheim
Buy
$38.00+59.5% to target
Coverage
—
+ Follow
#4
UE
Uy Ear
Mizuho
Buy
$35.00+46.9% to target
Coverage
—
+ Follow
#5
Tyler Van Buren
TD Cowen
Buy
$35.00+46.9% to target
Coverage
—
+ Follow
ARQT stock forecast FAQ
What is ARQT's average 12-month price target?+
The 7 analysts with a live target average $35.57 for Arcutis Biotherapeutics Inc over the next 12 months, ranging from a $40.00 high to a $29.00 low.
Is ARQT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 6 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ARQT?+
The Street-high target is $40.00 (Needham), and the Street-low is $29.00 (Goldman Sachs). The average of all 7 active targets is $35.57.
How many Wall Street analysts cover ARQT?+
7 analysts have an active rating on Arcutis Biotherapeutics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering ARQT?+
Among analysts who currently cover ARQT, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #105). Their current call is Buy with a $40.00 target.
What is Arcutis Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.23 per share (range $0.03 – $0.39) across 6 analysts. Full-year EPS is projected at $0.41, rising to $1.30 the following year.
How much revenue is Arcutis Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $160.1M (range $153.6M – $167.4M). Full-year revenue is projected at $536.9M, growing to $685.5M next year.
Have analysts been upgrading or downgrading ARQT lately?+
As of Sep, 6 of 7 firms rate ARQT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARQT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
